Oral infections and antibiotic therapy

Otolaryngologic Clinics of North America

Volumn 44, Issue 1, 2011, Pages 57-78

  Levi, Marilyn E ^a   Eusterman, Vincent D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Neck infection; Odontogenic infection; Oral infection

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DAPTOMYCIN; FAMCICLOVIR; FLUCONAZOLE; ITRACONAZOLE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MONOBACTAM; PENICILLIN G; SULFONAMIDE; VALACICLOVIR; VANCOMYCIN; VORICONAZOLE;

ANATOMY; ANTIBIOTIC THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEEP NECK INFECTION; DRUG INDUCED DISEASE; FUNGAL SINUSITIS; HEAD AND NECK INFECTION; HUMAN; MOUTH FLORA; MOUTH INFECTION; MUCOSA INFLAMMATION; RADIATION INJURY; REVIEW; TOOTH INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; FOCAL INFECTION, DENTAL; HERPES SIMPLEX; HUMANS; MALE; MOUTH; MOUTH DISEASES; MYCOSES;

EID: 78549269405     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2010.10.003     Document Type: Review

References (87)

1. Sichel J.Y., Attal P., Hocwald E., et al. Redefining parapharyngeal space infections. Ann Otol Rhinol Laryngol 2006, 115(2):117-123.
2. Dahlen G. Microbiology and treatment of dental abscesses and periodontal endodontic lesions. Periodontol 2000 2002, 28:206-239.
3. Preshaw P.M., Serymour R.A., Heasman P.A. Current concepts in periodontal pathogenesis. Dent bacterial diversity within the human subgingival crevice. Proc Natl Acad Sci U S A 1999, 96:14547-14552.
4. Brinig M.M., Lepp P.W., Ouverney C.C., et al. Prevalence of bacteria of division TM7 in human subgingival plaque and their association with disease. Appl Environ Microbiol 2003, 69:1678-1694.
5. Sutter V.L. Anaerobes as normal oral flora. Rev Infect Dis 1984, 6:S62.
6. Costello E.K., Lauber C.L., Hamady M., et al. Bacterial community variation in human body habitats over space and time. Science 2009, 326:1694.
7. Jousimies-Somer H., Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic gram-negative bacteria (excluding spirochetes). Clin Infect Dis 2002, 35(Suppl 1):517-521.
8. Chow A.W. Infections of the oral cavity, neck and head. Principles and practice of infectious diseases 2010, 855-871. Churchill Livingstone Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R.G. Douglas (Eds.).
9. Chow A.W. Odontogenic infections. Infections of the head and neck 1987, 148-160. Springer-Verlag, New York. D. Schlossberg (Ed.).
10. Selwitz R.H., Ismail A.I., Pitts N.B. Dental caries. Lancet 2007, 369:51-59.
11. Haffajee A.D., Cugini M.A., Tanner A., et al. Subgingival microbiota in healthy, well-maintained elder and periodontitis subjects. J Clin Periodontol 1998, 25:346-353.
12. Matto J., Asikainen S., Vaisanen M.L., et al. Role of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens in extraoral and some odontogenic infections. Clin Infect Dis 1997, 25(Suppl 2):S194-S198.
13. Brook I. Microbiology and management of endodontic infections in children. J Clin Pediatr Dent 2003, 28:13-17.
14. Hull M.W., Chow A.W. An approach to oral infections and their management. Curr Infect Dis Rep 2005, 7:17-27.
15. Epstein J.B. Mucositis in the cancer patient and immunosuppressed host. Infect Dis Clin North Am 2007, 21:503-522.
16. Ghuysen J.M. Molecular structure of penicillin-binding proteins and beta-lactamases. Trends Microbiol 1994, 2:372-380.
17. Kohanski M.A., Dwyer D.J., Hayete B., et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007, 130:797-810.
18. Marcy S.M., Klein J.O. The isoxazolyl penicillins: oxacillin, cloxacillin, and dicloxacillin. Med Clin North Am 1970, 54:1127-1143.
19. Herman D.J., Gerding D.N. Antimicrobial resistance among enterococci. Antimicrob Agents Chemother 1991, 35:1-4.
20. Mulligan M.E., Murray-Leisure K.A., Ribner B.S., et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis and epidemiology with implications for prevention and management. Am J Med 1993, 94:313.
21. Klimek J., Nightingale C., Lehmann W., et al. Comparisons of concentrations of amoxicillin in serum and middle ear fluid of children with chronic otitis media. J Infect Dis 1977, 155(6):999-1002.
22. Murphy TF. Haemophilus species (including H. influenzae and chancroid). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th edition. Philadelphia (PA): Churchill, Livingstone Elsevier; 2010. p. 2911-9.
23. Johnson G.J., White J.G. Proceedings: platelet dysfunction induced by parenteral administration of carbenicillin and ticarcillin. Thromb Diath Haemorrh 1975, 34(1):341-342.
24. Pichichero M.E. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005, 115:1048-1057.
25. Bohnen J.M., Solomkin J.S., Dellinger E.P., et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infections. Arch Surg 1992, 127:83.
26. Reichmann P., Konig A., Linares J., et al. A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis 1997, 176:1001.
27. Andes DR, Craig WA. Cephalosporins. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. 7th edition. Philadelphia (PA): Churchill, Livingstone Elsevier; 2010. p. 323-39.
28. Schaad U.B., Suter S., Gianella-Borradori A., et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990, 322:141.
29. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997, 24:S85.
30. Quagliarello V.J., Scheld W.M. Treatment of bacterial meningitis. N Engl J Med 1997, 336:708.
31. Barckow D., Schwigon C.D. Cefepime versus cefotaxime in the treatment of lower respiratory tract infection. J Antimicrob Chemother 1993, 32(Suppl B):187-193.
32. Zervos M., Nelson M., Cefepime Study Group Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 1998, 42:729-733.
33. Yun H.C., Ellis M.W., Jorgensen J.H. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn Microbiol Infect Dis 2007, 59(4):463.
34. Widmer A. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(5):656-658.
35. Noel G.J., Bush K., Bagchi P., et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008, 46(5):647-655.
36. Condon R.E., Walker A.P., Sirinek K.R., et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized double-blind clinical trial. Clin Infect Dis 1995, 21:544.
37. Chang D.C., Wilson S.E. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 1997, 174:284.
38. Available at:, Accessed October 14, 2010. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01728.html.
39. Kumarasamy K.K., Toleman M.A., Walsh T.R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
40. Dauner D.G., May J.R., Steele J.C. Assessing antibiotic therapy for Acinetobacter baumannii infections in an academic medical center. Eur J Clin Microbiol Infect Dis 2008, 27:1021-1024.
41. Maragakis I.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008, 46:1254-1263.
42. Jacobs R.F., Kearns G.I., Brown A.L., et al. Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections. Antimicrob Agents Chemother 1986, 29:670-674.
43. Nicolau D.P. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008, 47:532-540.
44. Calandra G., Lydick E., Carrigan J., et al. Factors predisposing to seizures in seriously ill patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988, 84:911.
45. Mohr J.F. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008, 47:S41-S51.
46. Keam S.J. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008, 68(14):2021-2057.
47. Chastre J., Wunderink R., Prokocimer P., et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36(4):1089-1096.
48. Barry A.L., Thornsberry C., Jones R.N., et al. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis 1985, 7:S594-S604.
49. Brummett R.E., Fox K.E. Aminoglycoside induced hearing loss in humans. Antimicrob Agents Chemother 1989, 33:797-800.
50. Ferguson B.J. What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis?. Otolaryngol Head Neck Surg 1998, 124(10):1174-1178.
51. Fausti S.A., Henry J.A., Schaffer H.I., et al. High frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992, 165:1026-1032.
52. Hutchin T., Cortopassi G. Proposed molecular and cellular mechanism of aminoglycoside ototoxicity. Antimicrob Agents Chemother 1994, 38:2517-2520.
53. Amiko M., Bagger-Sjoback D., et al. Gentamicin binding to the isolated crista ampullaris of the guinea pig. Res Commun Chem Pathol Pharmacol 1982, 37:333-342.
54. Minor L.B. Gentamicin-induced bilateral vestibular hypofunction. JAMA 1998, 279:541-544.
55. Singh Y.N., Harvey A.L., Marshall I.G. Antibiotic-induced paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and reversibility by calcium and by neostigmine. Anesthesiology 1978, 48:418-442.
56. Fairbanks DNF. Pocket guide to antimicrobial therapy in otolaryngology-head and neck surgery. 13th edition. Alexandria (VA): American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc; 2007. p. 10-11.
57. Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin and ketolides. In: Mandell GL, Douglas RG, Bennett JE. Principles and practice of infectious diseases. 7th edition. Philadelphia (PA): Churchill, Livingstone Elsevier; 2010. p. 427-48.
58. Bahal N., Nahata M.C. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, roxithromycin. Ann Pharmacother 1992, 26:46-55.
59. Credito K.L., Lin G., Pankuch G.A., et al. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001, 45:67-72.
60. Ednie L.M., Spangler S.K., Jacobs M.R., et al. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin and metronidazole. Antimicrob Agents Chemother 1997, 41:1037-1041.
61. Snydman D.R., Jacobus N.V., McDermott L.A., et al. National survey on the susceptibility of the Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2008, 51:1649-1655.
62. Dalmau D., Cayouette M., Lamothe F., et al. Clindamycin resistance in the Bacteroides fragilis group: association with hospital acquired infections. Clin Infect Dis 1997, 24:874-877.
63. Milazzo I., Blandino G., Caccamo F., et al. Faropenem, a new penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. J Antimicrob Chemother 2003, 51:721-725.
64. Salvatore M, Meyers BR. Metronidazole. In: Mandell GL, Douglas RG, Bennett JE. Principles and practice of infectious diseases. 7th edition. Philadelphia (PA): Churchill, Livingstone Elsevier; 2010. p. 419-26.
65. Geraci J.E., Heilman F.R., Nichols D.R., et al. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Proc Staff Meet Mayo Clin 1958, 33:172-191.
66. Forouzesh A.A., Moise P.A., Sakoulas G. Vancomycin ototoxicity: a re-evaluation in an era of increasing doses. Antimicrob Agents Chemother 2009, 53(2):483-486.
67. Murray BE, Nannini EC. Glycopeptides (vancomycin and teicoplanin), streptogramins (quinipristin-dalfopristin), and lipopeptides (daptomycin). In: Mandell GL, Douglas RG, Bennett JE. Principles and practice of infectious diseases. 7th edition. Philadelphia (PA): Churchill, Livingstone Elsevier; 2010. p. 449-67.
68. Matzke G.R., Zhanel G.G., Guay D.R. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986, 11:257-282.
69. O'Sullivan T.L., Ruffling M.J., Lamp K.C., et al. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis 1993, 168:773-776.
70. Downs N.J., Neihart R.E., Dolezal J.M., et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989, 149:1777-1781.
71. Rybak M.J., Albrecht L.M., Boike S.C., et al. Nephrotoxicity of vancomycin, alone or with an aminoglycoside. J Antimicrob Chemother 1990, 25:679-687.
72. Von Drygalski A., Curtis B.R., Bougie D.W., et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007, 356:904-910.
73. Farber B.F., Moellering R.C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983, 23:138-141.
74. 2+ and albumin on these drugs. Antimicrob Agents Chemother 2001, 45:454-459.
75. Akins R.L., Rybak M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacokinetic model with simulated endocardial vegetations. Antimicrobial Agents Chemother 2001, 45:454-459.
76. Yelland M.J. The efficacy of oral cotrimoxazole in the treatment of otitis externa in general practice. Med J Aust 1993, 158:697-699.
77. Leiberman A., Leibovitz E., Piglansky L., et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. Pediatr Infect Dis J 2001, 20:260-264.
78. McRae D., Buchanan G. Longterm sulfamethoxazole-trimethoprim in Wegener's granulomatosis. Arch Otolaryngol 1993, 119(1):103-105.
79. Rex JH, Stevens DA. Systemic antifungal agents. In: Mandell GL, Bennett JE, Douglas RG. Principles and practice of infectious diseases. 7th edition. Philadelphia (PA): Churchill, Livingstone Elsevier; 2010. p. 549-63.
80. Ponikau J.U., Sherris D.A., Weaver A., et al. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol 2005, 115(1):125-131.
81. Uscategui T., Doree C., Chamberlain I.J., et al. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008, 4. CD006851.
82. Lofti C.J., Cavalcanti R.C., Costa e Silva A.M., et al. Risk factors for surgical site infections in head and neck cancer surgery. Otolaryngol Head Neck Surg 2008, 138:74-80.
83. Brook I., Hirokawa R. Microbiology of wound infection after head and neck cancer surgery. Ann Otol Rhinol Laryngol 1989, 98:323-325.
84. Sharkawy A.A. Cervicofacial actinomycosis and mandibular osteomyelitis. Infect Dis Clin North Am 2007, 21:543-556.
85. Lockhart P.B., Durack D.T. Oral microflora as a cause of endocarditis and other distant site infections. Infect Dis Clin North Am 1999, 13:833-850.
86. Furst I.M., Ersil P., Caminiti M. A rare complication of tooth abscess-Ludwig's angina and mediastinitis. J Can Dent Assoc 2001, 67:324-327.
87. Garatea-Crelgo J., Gay-Escoda C. Mediastinitis from odontogenic infection. Report of three cases and review of the literature. Int J Oral Maxillofac Surg 1991, 20:65-68.